Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 3, 2018

Avacen Medical to study pain relief device for autism

Avacen Medical is set to investigate its US Food and Drug Administration (FDA) cleared AVACEN 100 device in a clinical trial for the treatment of autism behaviour.

Avacen Medical is set to investigate its US Food and Drug Administration (FDA) cleared AVACEN 100 device in a clinical trial for the treatment of autism behaviour.

AVACEN 100 is an over-the-counter, non-invasive medical device that is currently indicated to provide temporary relief for arthritis, muscle and joint pain.

The firm intends to submit the results from the double-blind, randomised, placebo-controlled study to the FDA for approval to treat social interaction and communication deficits, as well as for minimising anxiety level in autistic children and adolescents.

Planned for the first quarter of this year, the clinical study will assess the device in patients aged 6-16 years from military families in the San Diego region of the US.

Avacen Medical CEO Thomas Muehlbauer said: “We will be donating an AVACEN 100 to each family completing the study.

“Children who used the medical device for 15-30 minutes one or two times per day experienced relief from autistic behaviour.”

“If the child does not respond, our device can still offer benefits for each family member or their grandparents.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

“Although I admit there is geographical and cultural value inherent in using military subjects, we feel there is just as much value associated with helping the San Diego military community.”

According to the firm, children who used the medical device for 15-30 minutes one or two times per day experienced relief from autistic behaviour with improvements in speech, classroom participation and focus.

AVACEN 100 currently holds patents in the US, China, Australia, Japan, UK, France, Germany, Spain, Sweden, and Canada.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU